OBJECTIVE: To evaluate the short-term and long-term effects of plant-based medical cannabis in a chronic pain population over the course of one year. DESIGN: A longitudinal, prospective, 12-month observational study. SETTING: Patients were recruited and treated at a clinic specializing in medical cannabis care from October 2015 to March 2019. SUBJECTS: A total of 751 chronic pain patients initiating medical cannabis treatment. METHODS: Study participants completed the Brief Pain Inventory and the 12-item Short Form Survey (SF-12), as well as surveys on opioid medication use and adverse events, at baseline and once a month for 12 months. RESULTS: Medical cannabis treatment was associated with improvements in pain severity and interference (P < 0.001) observed at one month and maintained over the 12-month observation period. Significant improvements were also observed in the SF-12 physical and mental health domains (P < 0.002) starting at three months. Significant decreases in headaches, fatigue, anxiety, and nausea were observed after initiation of treatment (P ≤ 0.002). In patients who reported opioid medication use at baseline, there were significant reductions in oral morphine equivalent doses (P < 0.0001), while correlates of pain were significantly improved by the end of the study observation period. CONCLUSIONS: Taken together, the findings of this study add to the cumulative evidence in support of plant-based medical cannabis as a safe and effective treatment option and potential opioid medication substitute or augmentation therapy for the management of symptoms and quality of life in chronic pain patients.
OBJECTIVE: To evaluate the short-term and long-term effects of plant-based medical cannabis in a chronic pain population over the course of one year. DESIGN: A longitudinal, prospective, 12-month observational study. SETTING:Patients were recruited and treated at a clinic specializing in medical cannabis care from October 2015 to March 2019. SUBJECTS: A total of 751 chronic painpatients initiating medical cannabis treatment. METHODS: Study participants completed the Brief Pain Inventory and the 12-item Short Form Survey (SF-12), as well as surveys on opioid medication use and adverse events, at baseline and once a month for 12 months. RESULTS: Medical cannabis treatment was associated with improvements in pain severity and interference (P < 0.001) observed at one month and maintained over the 12-month observation period. Significant improvements were also observed in the SF-12 physical and mental health domains (P < 0.002) starting at three months. Significant decreases in headaches, fatigue, anxiety, and nausea were observed after initiation of treatment (P ≤ 0.002). In patients who reported opioid medication use at baseline, there were significant reductions in oral morphine equivalent doses (P < 0.0001), while correlates of pain were significantly improved by the end of the study observation period. CONCLUSIONS: Taken together, the findings of this study add to the cumulative evidence in support of plant-based medical cannabis as a safe and effective treatment option and potential opioid medication substitute or augmentation therapy for the management of symptoms and quality of life in chronic painpatients.
Authors: Michal Kawka; Simon Erridge; Carl Holvey; Ross Coomber; Azfer Usmani; Mohammad Sajad; Michael W Platt; James J Rucker; Mikael H Sodergren Journal: J Clin Pharmacol Date: 2021-10-05 Impact factor: 2.860